Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 348

1.

An update on familial nonmedullary thyroid cancer.

Ammar SA, Alobuia WM, Kebebew E.

Endocrine. 2020 Mar 11. doi: 10.1007/s12020-020-02250-3. [Epub ahead of print] Review.

PMID:
32162184
2.

The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.

Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W, Angelos P, Chen H, Doherty GM, Fahey TJ 3rd, Kebebew E, Livolsi VA, Perrier ND, Sipos JA, Sosa JA, Steward D, Tufano RP, McHenry CR, Carty SE.

Ann Surg. 2020 Mar;271(3):e21-e93. doi: 10.1097/SLA.0000000000003580.

PMID:
32079830
3.

Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.

Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W, Angelos P, Chen H, Doherty GM, Fahey TJ 3rd, Kebebew E, Livolsi VA, Perrier ND, Sipos JA, Sosa JA, Steward D, Tufano RP, McHenry CR, Carty SE.

Ann Surg. 2020 Mar;271(3):399-410. doi: 10.1097/SLA.0000000000003735.

PMID:
32079828
4.

A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.

Smith DC, Kroiss M, Kebebew E, Habra MA, Chugh R, Schneider BJ, Fassnacht M, Jafarinasabian P, Ijzerman MM, Lin VH, Mohideen P, Naing A.

Invest New Drugs. 2020 Jan 27. doi: 10.1007/s10637-020-00899-1. [Epub ahead of print]

PMID:
31984451
5.

A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).

Ghosh C, Kumar S, Kushchayeva Y, Gaskins K, Boufraqech M, Wei D, Gara SK, Zhang L, Zhang YQ, Shen M, Mukherjee S, Kebebew E.

Clin Cancer Res. 2020 Jan 14. doi: 10.1158/1078-0432.CCR-19-1606. [Epub ahead of print]

6.

30th Anniversary and The Future of Thyroid.

Kebebew E.

Thyroid. 2020 Jan;30(1):1. doi: 10.1089/thy.2019.0794. No abstract available.

PMID:
31842720
7.

Preoperative systemic inflammatory markers are prognostic indicators in recurrent adrenocortical carcinoma.

Gaitanidis A, Wiseman D, El Lakis M, Nilubol N, Kebebew E, Patel D.

J Surg Oncol. 2019 Dec;120(8):1450-1455. doi: 10.1002/jso.25760. Epub 2019 Nov 16.

PMID:
31733070
8.

NOP53 as A Candidate Modifier Locus for Familial Non-Medullary Thyroid Cancer.

Orois A, Gara SK, Mora M, Halperin I, Martínez S, Alfayate R, Kebebew E, Oriola J.

Genes (Basel). 2019 Nov 7;10(11). pii: E899. doi: 10.3390/genes10110899.

9.

Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III).

Thakur S, Tobey A, Daley B, Auh S, Walter M, Patel D, Nilubol N, Kebebew E, Patel A, Jensen K, Vasko V, Klubo-Gwiezdzinska J.

Front Oncol. 2019 Sep 18;9:905. doi: 10.3389/fonc.2019.00905. eCollection 2019.

10.

Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels.

Good ML, Malekzadeh P, Ruff SM, Gupta S, Copeland A, Pacak K, Nilubol N, Kebebew E, Patel D.

World J Surg. 2020 Feb;44(2):552-560. doi: 10.1007/s00268-019-05175-9.

PMID:
31531722
11.

Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy.

Buishand FO, Liu-Chittenden Y, Fan Y, Tirosh A, Gara SK, Patel D, Meerzaman D, Kebebew E.

Surgery. 2020 Jan;167(1):224-232. doi: 10.1016/j.surg.2019.04.067. Epub 2019 Sep 13.

PMID:
31522749
12.

Long noncoding RNAs in thyroid cancer.

Sedaghati M, Kebebew E.

Curr Opin Endocrinol Diabetes Obes. 2019 Oct;26(5):275-281. doi: 10.1097/MED.0000000000000497.

PMID:
31385810
13.

National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?

Tierney JF, Chivukula SV, Poirier J, Pappas SG, Schadde E, Hertl M, Kebebew E, Keutgen X.

J Clin Endocrinol Metab. 2019 Dec 1;104(12):5948-5956. doi: 10.1210/jc.2019-00915.

PMID:
31361313
14.

Solutions to Reduce Unnecessary Imaging-Reply.

Oren O, Kebebew E, Ioannidis JPA.

JAMA. 2019 Jun 11;321(22):2243. doi: 10.1001/jama.2019.4021. No abstract available.

PMID:
31184737
15.

MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.

Ruff SM, Ayabe RI, Malekzadeh P, Good ML, Wach MM, Gonzales MK, Tirosh A, Nilubol N, Pacak K, Kebebew E, Patel D.

J Surg Res. 2019 Nov;243:1-7. doi: 10.1016/j.jss.2019.04.086. Epub 2019 May 27.

PMID:
31146085
16.

Family Medicine Residents' Attitudes About Training in Ethiopia and the United States.

Gossa W, Jones C, Raiculescu S, Melaku M, Kebebew E, Zerihun M, Fetters MD.

Fam Med. 2019 May;51(5):424-429. doi: 10.22454/FamMed.2019.190022.

17.

Reply: Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

El Lakis M, Kebebew E.

Surgery. 2019 Jun;165(6):1246-1247. doi: 10.1016/j.surg.2019.02.003. Epub 2019 Mar 23. No abstract available.

PMID:
30910232
18.

ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS.

Tirosh A, Killian JK, Zhu YJ, Petersen D, Walling J, Mor-Cohen R, Neychev V, Stevenson H, Keutgen XM, Patel D, Nilubol N, Meltzer P, Kebebew E.

Endocr Pract. 2019 Jun;25(6):580-588. doi: 10.4158/EP-2018-0603. Epub 2019 Mar 13.

PMID:
30865533
19.

Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer type-specific.

Green P, Kebebew E.

Am J Surg. 2019 Jul;218(1):14-17. doi: 10.1016/j.amjsurg.2019.02.019. Epub 2019 Feb 14.

PMID:
30862353
20.

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma.

Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, Gonzales MK, Viana B, Alrezk R, Adams KT, Tena I, Chen A, Neuzil J, Raygada M, Kebebew E, Taieb D, O'Dorisio MS, O'Dorisio T, Civelek AC, Stratakis CA, Mercado-Asis L, Pacak K.

Front Oncol. 2019 Feb 22;9:53. doi: 10.3389/fonc.2019.00053. eCollection 2019.

21.

The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors.

Shell J, Tirosh A, Millo C, Sadowski SM, Assadipour Y, Green P, Patel D, Nilubol N, Kebebew E.

Eur J Radiol. 2019 Mar;112:130-135. doi: 10.1016/j.ejrad.2018.11.023. Epub 2018 Nov 22.

PMID:
30777201
22.

Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer.

Klubo-Gwiezdzinska J, Auh S, Gershengorn M, Daley B, Bikas A, Burman K, Wartofsky L, Urken M, Dewey E, Smallridge R, Chindris AM, Kebebew E.

JAMA Netw Open. 2019 Feb 1;2(2):e187754. doi: 10.1001/jamanetworkopen.2018.7754.

23.

Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.

Hurst Z, Liyanarachchi S, He H, Brock P, Sipos J, Nabhan F, Kebebew E, Green P, Cote GJ, Sherman S, Walker CJ, Chang YS, Xue S, Hollingsworth B, Li W, Genutis L, Menq E, de la Chapelle A, Jhiang SM.

Thyroid. 2019 Apr;29(4):530-539. doi: 10.1089/thy.2018.0687. Epub 2019 Feb 13.

PMID:
30654714
24.

Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.

Tirosh A, Mukherjee S, Lack J, Gara SK, Wang S, Quezado MM, Keutgen XM, Wu X, Cam M, Kumar S, Patel D, Nilubol N, Tyagi MV, Kebebew E.

Cancer. 2019 Apr 15;125(8):1247-1257. doi: 10.1002/cncr.31930. Epub 2019 Jan 8.

PMID:
30620390
25.

Curbing Unnecessary and Wasted Diagnostic Imaging.

Oren O, Kebebew E, Ioannidis JPA.

JAMA. 2019 Jan 22;321(3):245-246. doi: 10.1001/jama.2018.20295. No abstract available.

PMID:
30615023
26.

High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy.

Green P, Zagzag J, Patel D, Weinstein LS, Simonds WF, Blau J, Marx S, Kebebew E, Perrier N, Nilubol N.

Surgery. 2019 Jan;165(1):124-128. doi: 10.1016/j.surg.2018.04.064. Epub 2018 Nov 7.

PMID:
30414705
27.

Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Boufraqech M, Patel D, Nilubol N, Powers A, King T, Shell J, Lack J, Zhang L, Gara SK, Gunda V, Klubo-Gwiezdzinska J, Kumar S, Fagin J, Knauf J, Parangi S, Venzon D, Quezado M, Kebebew E.

Thyroid. 2019 Jan;29(1):79-92. doi: 10.1089/thy.2018.0424. Epub 2018 Dec 28.

28.

ASO Author Reflections: Systemic Inflammatory Markers in Pancreatic Neuroendocrine Tumors.

Gaitanidis A, Patel D, Kebebew E.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):874-875. doi: 10.1245/s10434-018-6948-x. Epub 2018 Oct 23. No abstract available.

PMID:
30353397
29.

Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

El Lakis M, Giannakou A, Nockel PJ, Wiseman D, Gara SK, Patel D, Sater ZA, Kushchayeva YY, Klubo-Gwiezdzinska J, Nilubol N, Merino MJ, Kebebew E.

Surgery. 2019 Jan;165(1):50-57. doi: 10.1016/j.surg.2018.05.075. Epub 2018 Oct 14.

30.

Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.

Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR, Kebebew E.

Semin Oncol. 2018 Aug;45(4):232-235. doi: 10.1053/j.seminoncol.2018.07.002. Epub 2018 Oct 11. Review.

PMID:
30318110
31.

Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.

Gara SK, Lack J, Zhang L, Harris E, Cam M, Kebebew E.

Nat Commun. 2018 Oct 9;9(1):4172. doi: 10.1038/s41467-018-06366-z.

32.

Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors.

Tirosh A, Journy N, Folio LR, Lee C, Leite C, Yao J, Kovacs W, Linehan WM, Malayeri A, Kebebew E, Berrington de González A.

Radiology. 2019 Jan;290(1):116-124. doi: 10.1148/radiol.2018180687. Epub 2018 Oct 9.

33.

Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors.

El Lakis M, Gianakou A, Nockel P, Wiseman D, Tirosh A, Quezado MA, Patel D, Nilubol N, Pacak K, Sadowski SM, Kebebew E.

JAMA Surg. 2019 Jan 1;154(1):40-45. doi: 10.1001/jamasurg.2018.3475.

34.

Aggressive resection of neuroendocrine tumor (NET) liver metastases: NET neutral or gain?

Cisco R, Lin D, Kebebew E.

Surgery. 2019 Jan;165(1):176-177. doi: 10.1016/j.surg.2018.08.019. Epub 2018 Sep 25. No abstract available.

PMID:
30266442
35.

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.

Nilubol N, Boufraqech M, Zhang L, Gaskins K, Shen M, Zhang YQ, Gara SK, Austin CP, Kebebew E.

Oncotarget. 2018 Aug 31;9(68):33030-33042. doi: 10.18632/oncotarget.26050. eCollection 2018 Aug 31.

36.

Neural monitoring in endocrine neck surgery.

El Lakis M, Kebebew E.

Gland Surg. 2018 Aug;7(Suppl 1):S86-S88. doi: 10.21037/gs.2018.03.08. No abstract available.

37.

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.

Shell J, Keutgen XM, Millo C, Nilubol N, Patel D, Sadowski S, Boufraqech M, Yang L, Merkel R, Atallah C, Herscovitch P, Kebebew E.

Int J Endocr Oncol. 2018 Feb 2;5(1):IJE04. doi: 10.2217/ije-2017-0005. eCollection 2018 Feb.

38.

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.

Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, Patel K, Umbricht C, Zeiger M, Kebebew E, Sherman E, Ghossein R, Fagin JA, Chan TA.

Cancer Cell. 2018 Aug 13;34(2):256-270.e5. doi: 10.1016/j.ccell.2018.07.002.

39.

Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.

Tirosh A, Nilubol N, Patel D, Kebebew E.

Endocr Pract. 2018 Aug;24(8):710-717. doi: 10.4158/EP-2018-0022. Epub 2018 Aug 7.

PMID:
30084688
40.

Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database.

Tella SH, Kommalapati A, Yaturu S, Kebebew E.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3566-3573. doi: 10.1210/jc.2018-00918.

PMID:
29982685
41.

The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.

Luo H, Tobey A, Auh S, Cochran C, Zemskova M, Reynolds J, Lima C, Burman K, Wartofsky L, Skarulis M, Kebebew E, Klubo-Gwiezdzinska J.

Clin Endocrinol (Oxf). 2018 Oct;89(4):481-488. doi: 10.1111/cen.13806. Epub 2018 Aug 13.

42.

Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection.

Nockel P, Tirosh A, El Lakis M, Gaitanidis A, Merkel R, Patel D, Nilubol N, Sadowski SM, Cochran C, Gorden P, Kebebew E.

Endocrine. 2018 Sep;61(3):422-427. doi: 10.1007/s12020-018-1633-1. Epub 2018 Jun 19.

PMID:
29923016
43.

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.

Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, Agarwal S, Klubo-Gwiezdzinska J.

Clin Cancer Res. 2018 Aug 15;24(16):4030-4043. doi: 10.1158/1078-0432.CCR-17-3167. Epub 2018 Apr 24.

44.

Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism.

Sadowski SM, Pusztaszeri M, Brulhart-Meynet MC, Petrenko V, De Vito C, Sobel J, Delucinge-Vivier C, Kebebew E, Regazzi R, Philippe J, Triponez F, Dibner C.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2189-2198. doi: 10.1210/jc.2017-02506.

PMID:
29659895
45.

Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.

Nilubol N, Yuan Z, Paciotti GF, Tamarkin L, Sanchez C, Gaskins K, Freedman EM, Cao S, Zhao J, Kingston DGI, Libutti SK, Kebebew E.

J Natl Cancer Inst. 2018 Sep 1;110(9):1019-1029. doi: 10.1093/jnci/djy003.

46.

Frequency and consequence of the recurrent YY1 p.T372R mutation in sporadic insulinomas.

Parekh VI, Modali SD, Welch J, Simonds WF, Weinstein LS, Kebebew E, Agarwal SK.

Endocr Relat Cancer. 2018 May;25(5):L31-L35. doi: 10.1530/ERC-17-0311. Epub 2018 Feb 21. No abstract available.

47.

Convolutional Invasion and Expansion Networks for Tumor Growth Prediction.

Zhang L, Lu L, Summers RM, Kebebew E, Yao J.

IEEE Trans Med Imaging. 2018 Feb;37(2):638-648. doi: 10.1109/TMI.2017.2774044.

48.

Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism.

El Lakis M, Nockel P, Gaitanidis A, Guan B, Agarwal S, Welch J, Simonds WF, Weinstein L, Marx S, Nilubol N, Patel D, Merkel R, Tirosh A, Kebebew E.

J Am Coll Surg. 2018 May;226(5):933-938. doi: 10.1016/j.jamcollsurg.2018.01.007. Epub 2018 Mar 2.

49.

Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery.

Nockel P, El Lakis M, Gaitanidis A, Merkel R, Patel D, Nilubol N, Prodanov T, Pacak K, Kebebew E.

Ann Surg. 2019 Apr;269(4):741-747. doi: 10.1097/SLA.0000000000002671.

PMID:
29334561
50.

In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.

Tirosh A, El Lakis M, Green P, Nockel P, Patel D, Nilubol N, Gara SK, Keutgen XM, Linehan WM, Kebebew E.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1631-1638. doi: 10.1210/jc.2017-02434.

Supplemental Content

Loading ...
Support Center